Otvori glavni meni

Lorcaserin (APD-356, Belviq,[5][6], Lorqess[7][8]) je lek protiv gojaznosti. On ima serotonergička svojstva i deluje kao anoreksik. FDA nije odobrila njegovu primenu 2010, zbog zabrinutosti za bezbednost i efikasnost leka.[9] [10]

Lorkaserin
(IUPAC) ime
(1R)-8-hloro-1-metil-2,3,4,5-tetrahidro-1H-3-benzazepin
Klinički podaci
Robne marke Belviq
Identifikatori
CAS broj 846589-98-8
ATC kod nije dodeljen
PubChem[1][2] 11658860
ChemSpider[3] 9833595
UNII 637E494O0Z YesY
ChEMBL[4] CHEMBL360328 YesY
Hemijski podaci
Formula C11H14ClN 
Mol. masa 195,688 g/mol
SMILES eMolekuli & PubHem
Farmakoinformacioni podaci
Licenca

US FDA:link

Trudnoća X(US)
Pravni status -only (SAD)
Način primene Oralno

Vidi jošUredi

ReferenceUredi

  1. Li Q, Cheng T, Wang Y, Bryant SH (2010). "PubChem as a public resource for drug discovery.". Drug Discov Today 15 (23-24): 1052–7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003.  edit
  2. Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). "Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities". Annual Reports in Computational Chemistry 4: 217–241. doi:10.1016/S1574-1400(08)00012-1. 
  3. Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). "Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining". J Cheminform 2 (1): 3. PMID 20331846. doi:10.1186/1758-2946-2-3.  edit
  4. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). "ChEMBL: a large-scale bioactivity database for drug discovery". Nucleic Acids Res 40 (Database issue): D1100–7. PMID 21948594. doi:10.1093/nar/gkr777.  edit
  5. "FDA approves Arena obesity drug; first in 13 years". Reuters. 27. 6. 2012.. http://www.reuters.com/article/2012/06/27/us-arena-obesity-idUSBRE85Q1AA20120627. 
  6. "Belviq". Trademarkia. 23 Jun 2011. http://www.trademarkia.com/belviq-85354490.html. pristupljeno 27. 6. 2012.. 
  7. "Lorqess". EvaluatePharma. 7. 9. 2010.. http://www.evaluatepharma.com/Universal/View.aspx?type=Entity&entityType=Product&id=43487&lType=modData&componentID=1002. pristupljeno 13. 9. 2010.. 
  8. "Lorqess". Trademarkia. 25. 3. 2010.. http://www.trademarkia.com/lorqess-77968131.html. pristupljeno 13. 9. 2010.. 
  9. Andrew Pollack (16. 9. 2010.). "F.D.A. Panel Urges Denial of Diet Drug". New York Times. 
  10. "FDA Issues Complete Response Letter for Lorcaserin New Drug Application". 23. 10. 2010. 

Spoljašnje vezeUredi